PMID- 26728163
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20190828
IS  - 1860-2002 (Electronic)
IS  - 1536-1632 (Linking)
VI  - 18
IP  - 4
DP  - 2016 Aug
TI  - Baseline [(18)F]FMISO muPET as a Predictive Biomarker for Response to HIF-1alpha 
      Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft 
      Model.
PG  - 606-16
LID - 10.1007/s11307-015-0926-5 [doi]
AB  - PURPOSE: The purpose of this study was to characterize imaging biomarkers for the 
      potential benefit of hypoxia-inducible factor-1 (HIF-1)alpha inhibition (by PX-12) 
      during 5-fluorouracil (5-FU) chemotherapy in the treatment of colorectal cancer 
      (CRC). PROCEDURES: Therapy response to 5-FU +/- PX-12 was assessed with baseline 
      [(18)F]fluoromisonidazole ([(18)F]FMISO) and longitudinal 
      2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) positron emission computed 
      tomography (muPET/CT) in CRC xenograft model (n = 36) during breathing of a 
      hypoxic (10 % O2) or normoxic (21 % O2) atmosphere. Ex vivo, immunohistochemistry 
      was performed. RESULTS: Baseline [(18)F]FMISO uptake and relative tumor volume 
      (RTV) 2 days after 5-FU or 5-FU + PX-12 administration correlated significantly 
      (p </= 0.01). Under hypoxic breathing conditions, [(18)F]FDG uptake (-53.1 +/- 8.4 %) 
      and Ki67 expression (-16 %) decreased and RTV stagnated in the 5-FU + PX-12 
      treatment group, but not in 5-FU alone-treated tumors. Under normoxic breathing, 
      [(18)F]FDG uptake (-23.5 +/- 15.2 % and -72.8 +/- 7.1 %) and Ki67 expression (-5 % 
      and -19 %) decreased and RTV stagnated in both the 5-FU and the combination 
      treatment group, respectively. CONCLUSION: Baseline [(18)F]FMISO muPET may predict 
      the beneficial effect of HIF-1alpha inhibition during 5-FU chemotherapy in CRC.
FAU - De Bruycker, Sven
AU  - De Bruycker S
AD  - Molecular Imaging Center Antwerp (MICA), University of Antwerp, 
      Universiteitsplein 1, Wilrijk, Antwerp, Belgium.
FAU - Vangestel, Christel
AU  - Vangestel C
AD  - Molecular Imaging Center Antwerp (MICA), University of Antwerp, 
      Universiteitsplein 1, Wilrijk, Antwerp, Belgium.
AD  - Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, 
      2650, Edegem, Antwerp, Belgium.
FAU - Van den Wyngaert, Tim
AU  - Van den Wyngaert T
AD  - Molecular Imaging Center Antwerp (MICA), University of Antwerp, 
      Universiteitsplein 1, Wilrijk, Antwerp, Belgium.
AD  - Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, 
      2650, Edegem, Antwerp, Belgium.
FAU - Wyffels, Leonie
AU  - Wyffels L
AD  - Molecular Imaging Center Antwerp (MICA), University of Antwerp, 
      Universiteitsplein 1, Wilrijk, Antwerp, Belgium.
AD  - Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, 
      2650, Edegem, Antwerp, Belgium.
FAU - Wouters, An
AU  - Wouters A
AD  - Center for Oncological Research (CORE), University of Antwerp, Universiteitsplein 
      1, Wilrijk, Antwerp, Belgium.
FAU - Pauwels, Patrick
AU  - Pauwels P
AD  - Center for Oncological Research (CORE), University of Antwerp, Universiteitsplein 
      1, Wilrijk, Antwerp, Belgium.
FAU - Staelens, Steven
AU  - Staelens S
AD  - Molecular Imaging Center Antwerp (MICA), University of Antwerp, 
      Universiteitsplein 1, Wilrijk, Antwerp, Belgium.
FAU - Stroobants, Sigrid
AU  - Stroobants S
AD  - Molecular Imaging Center Antwerp (MICA), University of Antwerp, 
      Universiteitsplein 1, Wilrijk, Antwerp, Belgium. sigrid.stroobants@uza.be.
AD  - Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, 
      2650, Edegem, Antwerp, Belgium. sigrid.stroobants@uza.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Imaging Biol
JT  - Molecular imaging and biology
JID - 101125610
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Fluorine Radioisotopes)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 082285VIDF (fluoromisonidazole)
RN  - 8FE7LTN8XE (Misonidazole)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Animals
MH  - Biomarkers, Tumor/*metabolism
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*diagnostic imaging/*drug therapy
MH  - Female
MH  - Fluorine Radioisotopes
MH  - Fluorouracil/*therapeutic use
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors/metabolism
MH  - Immunohistochemistry
MH  - Mice, Nude
MH  - Misonidazole/*analogs & derivatives/chemistry
MH  - Positron-Emission Tomography/*methods
MH  - Reproducibility of Results
MH  - *Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - 2-deoxy-2-[18F]fluoro-D-glucose
OT  - 5-fluorouracil
OT  - PX-12
OT  - Tumor hypoxia
OT  - [18F]fluoromisonidazole
EDAT- 2016/01/06 06:00
MHDA- 2017/09/28 06:00
CRDT- 2016/01/06 06:00
PHST- 2016/01/06 06:00 [entrez]
PHST- 2016/01/06 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
AID - 10.1007/s11307-015-0926-5 [pii]
AID - 10.1007/s11307-015-0926-5 [doi]
PST - ppublish
SO  - Mol Imaging Biol. 2016 Aug;18(4):606-16. doi: 10.1007/s11307-015-0926-5.